Premium
Protective Immune Response to 16 kDa Immunoreactive Recombinant Protein Encoding the C‐Terminal VP1 Portion of Foot and Mouth Disease Virus Type Asia 1
Author(s) -
Bayry Jagadeesh,
Prabhudas Krishnamsetty,
Gopalakrishna Susarla,
Patil Prasanna K.,
Ramakrishna Chitimalla,
Misra Laxmi Dutt,
Suryanarayana Veluvarti V. S.
Publication year - 1999
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.1999.tb02468.x
Subject(s) - adjuvant , virology , biology , recombinant dna , immune system , booster dose , foot and mouth disease virus , vaccination , virus , immunity , titer , microbiology and biotechnology , immunology , biochemistry , gene
Recombinant protein of Foot and Mouth Disease Virus (FMDV) type Asia 1 corresponding to the C‐terminal half of VP1 was expressed in Escherichia coli . As an alternative to the synthetic peptide, this selected C‐terminal region was used as a protein vaccine in guinea pigs in order to study the immune response with various adjuvant formulations: immune stimulatory complexes (ISCOMs), Montanide ISA 206, Freund's incomplete adjuvant (FIA), lipopolysaccharide (LPS) and cytokine mixture. A primary dose of 40 μg/animal followed by a booster of the same dose was injected after a 21‐day interval. The sera were collected at intervals of 21, 42 and 63 days after the booster. The humoral response to vaccine was monitored by sandwich enzyme‐linked immunosorbent assay (ELISA) and a serum neutralization test (SNT). The guinea pig sera showed high titers both in ELISA and SNT, which could be protective. Further, irrespective of the adjuvant preparation used, the vaccine conferred protection against the challenge virus 105 days post‐vaccination in 13 of 15 animals (86%). The results indicated that a combination of recombinant protein ISCOMs and Montanide ISA 206 would be a better choice for achieving early protective titers and longer lasting immunity and that the C‐terminal half of the VP1 protein may be tried as a safe vaccine for secondary immunization.